8-K: Altimmune Announces Positive Lean Mass Data for Pemvidutide and Reports Full Year 2023 Financial Results

Altimmune's pemvidutide shows promising lean mass preservation in a Phase 2 obesity trial, with 74.5% of weight loss from adipose tissue, and the company reports its full year 2023 financial results.

Summary

• Altimmune announced positive results from a body composition analysis of its Phase 2 MOMENTUM obesity trial for pemvidutide, showing that 74.5% of weight loss was from adipose tissue and only 25.5% from lean mass.
• This lean mass preservation is comparable to weight loss from diet and exercise.
• The company also reported its full year 2023 financial results, with $198 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
• Research and development expenses were $16.9 million for the quarter ended December 31, 2023, and $65.8 million for the full year.
• A Phase 2b trial for pemvidutide in MASH is ongoing, with topline 24-week data expected in the first quarter of 2025.
• A preclinical study showed pemvidutide has a direct anti-fibrotic effect in a non-steatotic model of liver fibrosis.
• The company has stopped further development of HepTcell due to insufficient response in a Phase 2 trial, resulting in a $12.4 million impairment loss.

Sentiment

Score: 8

Explanation: The document is positive due to the strong clinical results for pemvidutide, particularly the lean mass preservation and weight loss data. The company's cash position is also strong. However, the discontinuation of HepTcell and the net losses temper the overall sentiment slightly.

Positives

• Pemvidutide shows strong lean mass preservation, which is important for avoiding negative health outcomes.
• The drug has demonstrated significant weight loss and improvements in lipid profiles.
• Pemvidutide has shown a reduction in liver fat content.
• The company has a strong cash position of $198 million.
• Preclinical data suggests a direct anti-fibrotic effect of pemvidutide, which is promising for MASH treatment.
• Pemvidutide has received Fast Track designation from the FDA for the treatment of MASH.

Negatives

• The company has stopped development of HepTcell, resulting in a $12.4 million impairment loss.
• The company reported a net loss of $31.6 million for the quarter ended December 31, 2023, and a net loss of $88.4 million for the full year.
• Research and development expenses remain high at $16.9 million for the quarter and $65.8 million for the year.

Risks

• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for pemvidutide.
• The company is dependent on the success of pemvidutide, and the failure of this drug would have a significant negative impact.
• The company is incurring significant losses and may need to raise additional capital in the future.
• There are risks associated with manufacturing and supply chain interruptions.
• There are risks associated with access to clinical sites and enrollment.

Future Outlook

The company anticipates topline 24-week data from the IMPACT Phase 2b MASH trial in the first quarter of 2025 and plans to present the complete analysis of the MOMENTUM trial data at an upcoming scientific meeting. The company will continue to use the IR portion of its website as a means of disclosing material non-public information.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, stated that they are extremely pleased with the body composition analysis from the MOMENTUM trial.
• Vipin K. Garg believes that pemvidutide has the potential to distinguish itself broadly from other therapies for the treatment of obesity.
• Scott Harris, Chief Medical Officer, noted that the quality of weight loss is as important as the quantity of weight loss.
• Scott Harris believes that pemvidutide, if approved, could stand out as an attractive option for weight loss and weight maintenance.

Industry Context

The announcement is relevant to the obesity and MASH treatment markets, where there is a high unmet need for effective and safe therapies. The focus on lean mass preservation is a key differentiator in the obesity treatment space, as many weight loss drugs can lead to muscle loss. The development of a drug with direct anti-fibrotic effects is also significant in the MASH market.

Comparison to Industry Standards

• The reported 74.5% adipose tissue loss and 25.5% lean mass loss with pemvidutide is comparable to the effects historically associated with weight loss from diet and exercise programs, which is a positive result compared to some other weight loss drugs that may cause more lean mass loss.
• The 15.6% mean weight loss at week 48 on the 2.4mg dose is competitive with other GLP-1 based therapies such as Wegovy (semaglutide) which has shown around 15% weight loss at similar time points, however, direct comparisons are difficult due to differences in trial design and patient populations.
• The robust reductions in triglycerides (55.8%), total cholesterol (20.0%), and LDL cholesterol (17.4%) are also competitive with other GLP-1 based therapies and statins, indicating a potential for cardiovascular benefit.
• The normalization of liver fat content in up to 78.6% of subjects is a strong result, especially when compared to other MASH treatments that may not have such a direct effect on liver fat.
• The direct anti-fibrotic effect of pemvidutide in a preclinical model is a promising result, as many MASH treatments focus on reducing liver fat and inflammation, but not necessarily fibrosis directly. This could be a key differentiator for pemvidutide.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical data for pemvidutide and the company's strong cash position.
• Employees may be affected by the discontinuation of the HepTcell program.
• Patients with obesity and MASH may benefit from the development of pemvidutide.
• Creditors will be reassured by the company's strong cash position.

Next Steps

• The company will present the complete analysis of the MOMENTUM trial data at an upcoming scientific meeting.
• The company will continue enrollment in the IMPACT Phase 2b MASH trial.
• The company expects topline 24-week data from the IMPACT Phase 2b MASH trial in the first quarter of 2025.

Key Dates

Keywords

pemvidutide, obesity, MASH, lean mass, weight loss, liver fibrosis, clinical trial, GLP-1, glucagon, HepTcell, financial results